



**ASX ANNOUNCEMENT**

**30 May 2019**

## ***Cynata's Cymerus™ Technology Featured in ISCT Presentations***

*Four presentations by Professor John Rasko, AO, President of the ISCT, Professor Igor Slukvin, founder of Cynata, and Dr Kilian Kelly, COO, to review results of Cynata's world-first clinical trial and highlight clinical use and development plans for the Cymerus™ technology*

**Melbourne, Australia; 30 May 2019:** Cynata Therapeutics Limited (ASX: CYP), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce that its Cymerus™ technology will be featured in several presentations at the Annual Meeting of the International Society of Cell and Gene Therapy (ISCT), which is taking place this week in Melbourne. The ISCT Annual Meeting attracts over one thousand delegates from around 50 countries and represents the peak international meeting of scientists, thought leaders, companies and investors in cell therapy.

Professor John Rasko, AO, will present results from Cynata's Phase 1 clinical trial of CYP-001 for the treatment of steroid-resistant acute graft versus host disease (GvHD) in a plenary session on Clinical Applications of Human Pluripotent Stem Cells. Professor Rasko is Head of the Gene and Stem Cell Therapy Program, Centenary Institute; Head of Department at Cell & Molecular Therapies, Royal Prince Alfred Hospital, Sydney; Professor at Sydney Medical School, University of Sydney; and President of the ISCT.

CYP-001 is Cynata's lead Cymerus mesenchymal stem cell (MSC) product candidate. The Phase 1 trial of CYP-001 represents the first time a clinical trial using induced pluripotent stem cell (iPSC)-derived MSCs has been completed.

Professor Igor Slukvin, founder of Cynata, inventor of the Cymerus technology, and Professor, Pathology & Laboratory Medicine at the University of Wisconsin-Madison, will present at a plenary satellite session on Production of iPSCs for Clinical Use.

Additionally, Dr Kilian Kelly, Cynata's Chief Operating Officer, will give two presentations on development plans for the Cymerus technology.

### **Details of Presentations:**

#### Thursday 30 May

Time:	11am
Session Title:	Strategies for Commercialization Track Session 1 – Think Big and Think Early to Prevent Failure at Commercial Scale
Presentation Title:	Plans for Global Roll Out of An Off-The-Shelf Allogeneic Cellular Therapy
Presenter:	Dr Kilian Kelly



#### Friday 31 May

Time: 8:45am  
Session Title: Plenary 3 – ISCT-JSRM Joint Session: Clinical Applications of Human Pluripotent Stem Cells  
Presentation Title: Addressing the cell scalability challenge head-on: Results of the First Completed Trial of iPSC-Derived MSCs in Steroid-Resistant Acute GvHD  
Presenter: Prof John Rasko

Time: 10:45am  
Session Title: Plenary 3 Satellite Session – Production of iPSCs for Clinical Use  
Presentation Title: Clinical Translation of Induced Pluripotent Stem Cell-Derived Off-the-Shelf Cellular Therapies  
Presenter: Prof Igor Slukvin

Time: 12:30pm  
Session Title: ISCT Global Showcase  
Presentation Title: Cymerus™ - Clinical Development Update  
Presenter: Dr Kilian Kelly

#### **Ends**

**CONTACTS:** Dr Ross Macdonald, CEO, Cynata Therapeutics, +61 (0)412 119343, [ross.macdonald@cynata.com](mailto:ross.macdonald@cynata.com)  
Rosa Smith, Australia Media Contact, +61 (0) 475 305 047, [rosa.smith@mcpartners.com.au](mailto:rosa.smith@mcpartners.com.au)  
Claire LaCagnina, U.S. Media Contact, +1 315.765.1462, [clacagnina@6degreespr.com](mailto:clacagnina@6degreespr.com)

#### **About Cynata Therapeutics (ASX: CYP)**

Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical-stage stem cell and regenerative medicine company focused on the development of therapies based on Cymerus™, a proprietary therapeutic stem cell platform technology. Cymerus overcomes the challenges of other production methods by using induced pluripotent stem cells (iPSCs) and a precursor cell known as mesenchymoangioblast (MCA) to achieve economic manufacture of cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale and without the limitation of multiple donors.

Cynata's lead product candidate CYP-001 met all clinical endpoints and demonstrated positive safety and efficacy data for the treatment of steroid-resistant acute graft-versus-host disease (GvHD) in a Phase 1 trial. Cynata plans to advance its Cymerus™ MSCs into Phase 2 trials for GvHD, critical limb ischemia and osteoarthritis. In addition, Cynata has demonstrated utility of its Cymerus MSC technology in preclinical models of asthma, diabetic wounds, heart attack and cytokine release syndrome, a life-threatening condition stemming from cancer immunotherapy.